INSULET CORP
PODDNASDAQTrading Snapshot
- Day Range
- $146.62 – $150.58
- 52-Week Range
- $126.40 – $354.88
- Volume (shares)
- 1,034,997
- Avg Volume (shares)
- —
- Shares Outstanding
- 69.3M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $2.71B
- Last Q Revenue
- $802M
- P/E Ratio
- 27.4
- P/S Ratio
- 3.4x
- EPS (TTM)
- $5.35
- Dividend Yield
- —
- Dilution (1yr)
- −4.6%
INSULET CORP
PODD
StockOtter · stockotter.spaceAbout INSULET CORP
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program
Insulet Corporation $PODD Shares Sold by Curated Wealth Partners LLC
Curated Wealth Partners LLC lessened its holdings in shares of Insulet Corporation (NASDAQ: PODD) by 83.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commiss
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Announces Omnipod Discover Now Available in U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discov
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financ